---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-114695"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2026-10-08T20:05:15+00:00"
generated_at: "2026-10-12T15:30:07.072230+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# TELA Bio holders approve 1-for-5 to 1-for-15 reverse split; no split planned after Nasdaq compliance regained

## Summary
- Special Meeting held October 8, 2026; 45,143,410 common shares outstanding as of the September 8, 2026 record date.
- Proposal 1 approved: 30,515,571 votes for, 80,512 against, 1,737,011 abstentions, 0 broker non-votes.
- Amendment would combine shares at a ratio of not less than one-for-five and not more than one-for-fifteen, exact ratio set by the Board in its sole discretion.
- Proposal 2 (adjournment if needed) approved: 30,757,679 for, 123,860 against, 1,451,555 abstentions.
- October 5, 2026 Nasdaq letter stated the company regained compliance with Listing Rule 5450(a)(1) minimum bid price; TELA Bio does not intend to effect the reverse split at this time.

## SEC filing metadata
- accession: 0001104659-26-114695
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2026-10-08T20:05:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465926114695/0001104659-26-114695-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465926114695/tm2627202d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-114695
- JSON: https://secwatch.observer/filing/0001104659-26-114695.json
- Plain text: https://secwatch.observer/filing/0001104659-26-114695.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.